Update on integrated biomarkers for assessment of long-term risk of cardiovascular complications in initially healthy subjects and patients with manifest atherosclerosis

References

• Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97: 1837–47
   PubMed Web of Science ®Google Scholar
• Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Münster (PROCAM) study. Circulation. 2002; 105: 310–5
   PubMed Web of Science ®Google Scholar
• De Backer, G, Ambrosioni, E, Borch-Johnsen, K, Brotons, C, Cifkova, R, Dallongeville, J, , et al. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003;24:1601–10.
   Google Scholar
• Greenland P. Improving risk of coronary heart disease: can a picture make the difference?. JAMA. 2003; 289: 2270–2
   Google Scholar
• Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003; 290: 898–904
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ, Morris JK. The performance of blood pressure and other cardiovascular risk factors as screening tests for ischaemic heart disease and stroke. J Med Screen. 2004; 11: 3–7
   PubMed Web of Science ®Google Scholar
• Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002; 106: 388–91
   PubMed Web of Science ®Google Scholar
• Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol. 2007; 27: 15–26
   PubMed Web of Science ®Google Scholar
• Bisoendial RJ, Kastelein JJ, Stroes ES. C-reactive protein and atherogenesis: from fatty streak to clinical event. Atherosclerosis. 2007; 195: e10–18
   PubMed Web of Science ®Google Scholar
• ; The Emerging Risk Factors CollaborationDanesh, J, Ergou, S, Walker, M, Thompson, SG, Tipping, R, Ford, C, , et al. The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol. 2007;22:839–69.
   Google Scholar
• Kimberly MM, Vesper HW, Caudill SP, Cooper GR, Rifai N, Dati F, et al. Standardization of immunoassays for measurement of high-sensitivity C-reactive protein. Phase I: evaluation of secondary reference materials. Clin Chem. 2003; 49: 611–6
   PubMed Web of Science ®Google Scholar
• Pearson, TA, Mensah, GA, Alexander, RW, Anderson, JL, Cannon, RO 3rd, Criqui, M, ; Centers for Disease Control and Prevention, et al; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511.
   Google Scholar
• ; Fibrinogen Studies CollaborationDanesh, J, Lewington, S, Thompson, SG, Lowe, GD, Collins, R, Kostis, JB, , et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294:1799–809.
   Google Scholar
• Khuseyinova N, Koenig W. Predicting the risk of cardiovascular disease: where does lipoprotein-associated phospholipase A(2) fit in?. Mol Diagn Ther. 2007; 11: 203–17
   Google Scholar
• Mora S, Rifai N, Buring JE, Ridker PM. Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events. Circulation. 2006; 114: 381–7
   PubMed Web of Science ®Google Scholar
• Lowe GD, Sweetnam PM, Yarnell JW, Rumley A, Rumley C, Bainton D, et al. C-reactive protein, fibrin D-dimer, and risk of ischemic heart disease: the Caerphilly and Speedwell studies. Arterioscler Thromb Vasc Biol. 2004; 24: 1957–62
   PubMed Web of Science ®Google Scholar
• Engström G, Lind P, Hedblad B, Stavenow L, Janzon L, Lindgärde F. Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men. Circulation. 2002; 105: 2632–7
   PubMed Web of Science ®Google Scholar
• Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation. 2007; 115: 2119–27
   PubMed Web of Science ®Google Scholar
• Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003; 108: 414–9
   PubMed Web of Science ®Google Scholar
• Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003; 107: 391–7
   PubMed Web of Science ®Google Scholar
• Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation. 2004; 110: 1903–8
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Chambless LE, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2005; 165: 2479–84
   PubMedGoogle Scholar
• Winkler K, Hoffmann MM, Winkelmann BR, Friedrich I, Schäfer G, Seelhorst U, et al. Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem. 2007; 53: 1440–7
   PubMed Web of Science ®Google Scholar
• Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol. 2007; 27: 1788–95
   PubMed Web of Science ®Google Scholar
• Koenig W, Khuseyinova N, Baumert J, Meisinger C, Löwel H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol. 2006; 48: 1369–77
   PubMed Web of Science ®Google Scholar
• Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006; 355: 2631–9
   PubMed Web of Science ®Google Scholar
• Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008; 358: 2107–16
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Lloyd-Jones DM. Multiple biomarker panels for cardiovascular risk assessment. N Engl J Med. 2008; 358: 2172–4
   PubMed Web of Science ®Google Scholar
• Blankenberg S, McQueen MJ, Smieja M, Pogue J, Balion C, Lonn E, et al. HOPE Study Investigators. Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2006; 114: 201–8
   PubMed Web of Science ®Google Scholar
• Kathiresan S, Melander O, Anevski D, Guiducci C, Burtt NP, Roos C, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med. 2008; 358: 1240–9
   PubMed Web of Science ®Google Scholar
• Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004; 291: 210–5
   PubMed Web of Science ®Google Scholar
• Arad Y, Goodman KJ, Roth M, Newstein D, Guerci AD. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. J Am Coll Cardiol. 2005; 46: 158–65
   PubMed Web of Science ®Google Scholar
• Budoff MJ, Shaw LJ, Liu ST, Weinstein SR, Mosler TP, Tseng PH, et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol. 2007; 49: 1860–70
   PubMed Web of Science ®Google Scholar
• Lakoski SG, Greenland P, Wong ND, Schreiner PJ, Herrington DM, Kronmal RA, et al. Coronary artery calcium scores and risk for cardiovascular events in women classified as ‘low risk’ based on Framingham risk score: the Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med. 2007; 167: 2437–42
   PubMed Web of Science ®Google Scholar
• Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008; 358: 1336–45
   PubMed Web of Science ®Google Scholar
• Budoff, MJ, Achenbach, S, Blumenthal, RS, Carr, JJ, Goldin, JG, Greenland, P, ; American Heart Association Committee on Cardiovascular Imaging and Intervention, et al; American Heart Association Council on Cardiovascular Radiology and Intervention; American Heart Association Committee on Cardiac Imaging; Council on Clinical Cardiology. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation. 2006;114:1761–91.
   Google Scholar
• Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007; 115: 459–67
   PubMed Web of Science ®Google Scholar
• Baldassarre D, Amato M, Pustina L, Castelnuovo S, Sanvito S, Gerosa L, et al. Measurement of carotid artery intima-media thickness in dyslipidemic patients increases the power of traditional risk factors to predict cardiovascular events. Atherosclerosis. 2007; 191: 403–8
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med. 1998; 128: 262–9
   PubMed Web of Science ®Google Scholar
• Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989; 8: 431–40
   PubMed Web of Science ®Google Scholar
• Oliver JJ, Webb DJ. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. Arterioscler Thromb Vasc Biol. 2003; 23: 554–66
   PubMed Web of Science ®Google Scholar
• Cohn JN. Arterial stiffness, vascular disease, and risk of cardiovascular events. Circulation. 2006; 113: 601–3
   PubMed Web of Science ®Google Scholar
• Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos ML, Schalekamp MA, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation. 2006; 113: 657–63
   PubMed Web of Science ®Google Scholar
• Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation. 2006; 113: 664–70
   PubMed Web of Science ®Google Scholar
• Heald, CL, Fowkes, FG, Murray, GD, Price, JF; Ankle Brachial Index Collaboration. Risk of mortality and cardiovascular disease associated with the ankle-brachial index: systematic review. Atherosclerosis. 2006;189:61–9.
   Google Scholar
• Golomb BA, Dang TT, Criqui MH. Peripheral arterial disease: morbidity and mortality implications. Circulation. 2006; 114: 688–99
   PubMed Web of Science ®Google Scholar
• Diehm C, Lange S, Darius H, Pittrow D, von Stritzky B, Tepohl G, et al. Association of low ankle brachial index with high mortality in primary care. Eur Heart J. 2006; 27: 1743–9
   PubMed Web of Science ®Google Scholar
• Lee AJ, Price JF, Russell MJ, Smith FB, van Wijk MC, Fowkes FG. Improved prediction of fatal myocardial infarction using the ankle brachial index in addition to conventional risk factors: the Edinburgh Artery Study. Circulation. 2004; 110: 3075–80
   PubMed Web of Science ®Google Scholar
• Wyman RA, Keevil JG, Busse KL, Aeschlimann SE, Korcarz CE, Stein JH. Is the ankle-brachial index a useful screening test for subclinical atherosclerosis in asymptomatic, middle-aged adults?. WMJ. 2006; 105: 50–4
   Google Scholar
• Fowkes, FG, Murray, GD, Butcher, I, Heald, CL, Lee, RJ, Chambless, LE, ; for Ankle Brachial Index Collaboration, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300:197–208.
   Google Scholar
• Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003; 108: 1664–72
   PubMed Web of Science ®Google Scholar
• Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation. 2003; 108: 1772–8
   PubMed Web of Science ®Google Scholar
• Waxman S, Ishibashi F, Muller JE. Detection and treatment of vulnerable plaques and vulnerable patients: novel approaches to prevention of coronary events. Circulation. 2006; 114: 2390–411
   PubMed Web of Science ®Google Scholar
• Simon A, Chironi G, Levenson J. Comparative performance of subclinical atherosclerosis tests in predicting coronary heart disease in asymptomatic individuals. Eur Heart J. 2007; 28: 2967–71
   PubMed Web of Science ®Google Scholar
• Jacobs DR, Jr, Crow RS. Subclinical cardiovascular disease markers applicable to studies of oral health: multiethnic study of atherosclerosis. Ann N Y Acad Sci. 2007; 1098: 269–87
   Google Scholar
• Bots ML, Baldassarre D, Simon A, de Groot E, O'Leary DH, Riley W, et al. Carotid intima-media thickness and coronary atherosclerosis: weak or strong relations?. Eur Heart J. 2007; 28: 398–406
   PubMed Web of Science ®Google Scholar
• Price JF, Tzoulaki I, Lee AJ, Fowkes FG. Ankle brachial index and intima media thickness predict cardiovascular events similarly and increased prediction when combined. J Clin Epidemiol. 2007; 60: 1067–75
   PubMed Web of Science ®Google Scholar
• Park R, Detrano R, Xiang M, Fu P, Ibrahim Y, LaBree L, et al. Combined use of computed tomography coronary calcium scores and C-reactive protein levels in predicting cardiovascular events in nondiabetic individuals. Circulation. 2002; 106: 2073–7
   PubMed Web of Science ®Google Scholar
• Cao JJ, Arnold AM, Manolio TA, Polak JF, Psaty BM, Hirsch CH, et al. Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study. Circulation. 2007; 116: 32–8
   PubMed Web of Science ®Google Scholar
• Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol. 2004; 159: 882–90
   PubMed Web of Science ®Google Scholar
• Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation. 2007; 115: 949–52
   PubMed Web of Science ®Google Scholar
• Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007; 115: 928–35
   PubMed Web of Science ®Google Scholar
• Pencina MJ, D'Agostino RB Sr, D'Agostino RB, Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008; 27: 157–72
   PubMed Web of Science ®Google Scholar
• Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007; 297: 611–19
   PubMed Web of Science ®Google Scholar
• Arab S, Gramolini AO, Ping P, Kislinger T, Stanley B, van Eyk J, et al. Cardiovascular proteomics: tools to develop novel biomarkers and potential applications. J Am Coll Cardiol. 2006; 48: 1733–41
   PubMed Web of Science ®Google Scholar
• Jaffer FA, Libby P, Weissleder R. Molecular and cellular imaging of atherosclerosis: emerging applications. J Am Coll Cardiol. 2006; 47: 1328–38
   PubMed Web of Science ®Google Scholar
• Laaksonen R, Katajamaa M, Päivä H, Sysi-Aho M, Saarinen L, Junni P, et al. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS ONE. 2006; 1: e97
   PubMed Web of Science ®Google Scholar
• Stern S. Are we getting nearer to screening for atherosclerosis?. Circulation. 2008; 117: 122–6
   Google Scholar